GLP-1 may slow biological aging
- ID
- 36852
- Status
- summarized
- Published
- 18 Oct 2026, 12:10 AM
- Fetched
- 19 Oct 2026, 6:03 AM
- Provider
- Hacker News
- Category
- dev-community
- Original URL
- https://www.universityofcalifornia.edu/news/new-study-shows-popular-glp-1-weight-loss-drug-may-slow-biological-aging
- Source URL
- https://hnrss.org/best
Summary
- Score
- 1.5
- Created
- 19 Oct 2026, 6:03 AM
- Tags
- Audience
- -
What happened
A UC San Diego-led randomized, double-blind, placebo-controlled trial found that semaglutide (sold as Ozempic/Wegovy) slowed biological aging across multiple epigenetic clocks, per a UC news piece published June 11, 2026 and written by Susanne Clara Bard. The article text provided is truncated and does not include the measured effect sizes, trial duration, sample size, or which specific clocks moved. It drew 180 points and 177 comments on Hacker News.
Why it matters
Nothing here changes what a developer, agent builder, or SaaS founder ships this week — it is a clinical-trial result in a health-science story, and the excerpt omits the numbers (effect size, n, trial length) that would let anyone judge how meaningful the epigenetic-clock change is. Skip it for the build segment unless you want a two-minute aside on why health/self-optimization threads consistently outrank actual dev tooling on HN.
Discussion angle
Worth one line only: note that the source text stops before any effect size, so the 177-comment thread is reacting to a headline, not a measurement — a useful reminder of how we read 'study shows' claims in our own AI benchmark announcements too.